Claims for Patent: 8,206,740

Summary for Patent: 8,206,740

Title:	Once daily formulations of tetracyclines
Abstract:	Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Inventor(s):	Chang; Rong-Kun (Rockville, MD), Raoufinia; Arash (Springfield, VA), Shah; Niraj (Owings Mills, MD)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	12/155,676
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,206,740
Patent Claims:	1. An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 .mu.g/ml and a maximum of 1.0 .mu.g/ml, the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline; (ii) a delayed release (DR) portion comprising 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients. 2. The composition of claim 1, which at a once-daily dosage will give steady state blood levels of the doxycycline of between 0.3 .mu.g/ml to 0.8 .mu.g/ml. 3. The composition of claim 1, wherein the ratio of IR to DR is from 99:1 to 70:30. 4. The composition of claim 3, wherein the ratio of IR to DR is from 80:20 to 70:30. 5. The composition of claim 4, wherein the ratio of IR to DR is 75:25. 6. The composition of claim 1, which is in the form of a granule, tablet, pellet, powder, sachet, capsule, gel, dispersion or suspension. 7. The composition of claim 1, which is in a dosage form of a combination of pellets. 8. The composition according to claim 1, wherein the DR portion comprises at least one enteric polymer. 9. The composition of claim 8, wherein the enteric polymer is cellulose acetate phthalate; hydroxypropyl methylcellulose phthalate; polyvinyl acetate phthalate; hydroxypropyl methylcellulose acetate succinate; cellulose acetate trimellitate; hydroxypropyl methylcellulose succinate; cellulose acetate succinate; cellulose acetate hexahydrophthalate; cellulose propionate phthalate; a copolymer of methylmethacrylic acid and methyl methacrylate; a copolymer of methyl acrylate, methylmethacrylate and methacrylic acid; a copolymer of methylvinyl ether and maleic anhydride; ethyl methyacrylate -methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer; zein; shellac; poly(methacylic acid-co-ethyl acrylate) 1:1, or combinations thereof. 10. The composition according to claim 1, wherein the DR formulation is in the form of granules, pellets, or tablet. 11. The composition according to claim 1, wherein the one or more pharmaceutically acceptable excipients is incorporated in the IR portion, the DR portion, or both. 12. The composition of claim 11, wherein the one or more pharmaceutically acceptable excipients is a binder, a disintegration agent, a filling agent, a surfactant, a solubilizer, a stabilizer, and combinations thereof. 13. The composition of claim 12, wherein the binder is selected from the group consisting of methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, and polyvinylpyrrolidone/vinyl acetate copolymer. 14. The composition of claim 12, wherein the disintegration agent is selected from the group consisting of cornstarch, pregelatinized starch, cross-linked carboxymethylcellulose, sodium starch glycolate, and cross-linked polyvinylpyrrolidone. 15. The composition of claim 12, wherein the filling agents are selected from the group consisting of lactose, calcium carbonate, calcium phosphate, calcium sulfate, microcrystalline cellulose, dextran, starches, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, and polyethylene glycol. 16. The composition of claim 12, wherein the surfactants are selected from the group consisting of sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, bile salts, and glyceryl monostearate. 17. The composition of claim 12, wherein the solubilizers are selected from the group consisting of citric acid, succinic acid, fumaric acid, malic acid, tartaric acid, maleic acid, glutaric acid, sodium bicarbonate, and sodium carbonate. 18. The composition of claim 12, wherein the stabilizers are selected from the group consisting of antioxidation agents, buffers, and acids. 19. A method for treating rosacea in a mammal in need thereof, comprising administering an oral pharmaceutical composition of doxycycline comprising, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 .mu.g/ml and a maximum of 1.0 .mu.g/ml, the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline; (ii) a delayed release (DR) portion comprising 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients. 20. The method of claim 19, wherein the mammal is a human. 21. The method of claim 19, which at a once-daily dosage, administration of the composition will give steady state blood levels of the doxycycline of between 0.3 .mu.g/ml to 0.8 .mu.g/ml. 22. A process for preparing a once-daily oral pharmaceutical composition according to claim 1, which will give steady state blood levels of the tetracycline of a minimum of 0.1 .mu.g/ml and a maximum of 1.0 .mu.g/ml, comprising combining (i) an immediate release (IR) portion comprising 30 mg doxycycline; (ii) a delayed release (DR) portion comprising 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients. 23. A delayed-release tablet of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 .mu.g/ml and a maximum of 1.0 .mu.g/ml, the tablet consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline in the form of tablet; (ii) a delayed release (DR) portion comprising 10 mg doxycycline; and, optionally, (iii) one or more pharmaceutically acceptable excipients. 24. The delayed-release tablet of claim 23, wherein the delayed release (DR) portion is present as a core and the immediate-release (IR) portion as an outer layer atop the core. 25. The delayed-release tablet of claim 23, which at a once-daily dosage will give steady state blood levels of the doxycycline of between 0.3 .mu.g/ml to 0.8 .mu.g/ml. 26. The delayed-release tablet of claim 23, wherein the one or more pharmaceutically acceptable excipients is incorporated in the IR portion, the DR portion, or both. 27. The delayed-release tablet of claim 23, wherein the one or more pharmaceutically acceptable excipients is a binder, a disintegration agent, a filling agent, a surfactant, a solubilizer, a stabilizer, and combinations thereof. 28. A method for treating rosacea in a mammal in need thereof, comprising administering to the mammal a delayed-release tablet of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 .mu.g/ml and a maximum of 1.0 .mu.g/ml, wherein the tablet consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline in the form of tablet; (ii) a delayed release (DR) portion comprising 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients. 29. The method of claim 28, wherein the mammal is a human.